Full Program
RE(ACT) Congress & IRDiRC Conference 2023
This program is subject to change without notice at any time.
WEDNESDAY, MARCH 15th
Session A, 13h30 to 17, « Diagnostic, WGS, artificial intelligence, new technologies »
- Martina Cornel, NL
- Julia Foreman, UK « DECIPHER – Enabling the sharing of rare disease phenotype-linked variant data for diagnosis and research »
- Clara van Karnebeek, NL
- Pierre-Emmanuel Gleizes, FR
- Tudor Groza, UK « Rare disease patient stratification in primary care: Challenges and opportunities »
- Kym Boycott, CAN
Poster Session A 17 to 18
Opening Ceremony, 18 to 19h30
THURSDAY, MARCH 16th
Session B, 9 to 12, « Therapeutic Development, innovative clinical trials, precision medicine »
- Marc Dooms, BE & Anneliene Jonker, NL « Devise – ways forward for medical devices for rare diseases »
- Tim Buckinx, BE
- Lucia Pannese, IT « Why Me? Tackling the Challenge of Rare Diseases through Gamification and Enabling Technologies »
- Jose-Alain Sahel, FR
- Paulien Klap, NL « Developing an arm exoskeleton with the Duchenne Muscular Dystrophy community »
Lunch break and poster sessions B & C 12 to 13h30
Session C, 13h30 to 17, « Regulatory science »
- Daniel O’Connor, UK
- Anne Pariser, USA “Regulatory opportunities: Facilitating an environment of innovation”
- Kerry Jo Lee, USA
- Julie Vaillancourt, USA
FRIDAY, MARCH 17th
Session D, 9 to 12, « Clinical research »
- Marta Alarcón-Riquelme, ES
- Isabella Batsu, USA « Innovative clinical trial designs for rare diseases »
- PJ Brooks, USA
- Andrea Gropman, USA « From biomarker to study to basket clinical trials. Advancing science from the bedside or bench to trials: two models in academia »
Lunch break and poster sessions D, E & F 12 to 13h30
Session E, 13 to 17, « Gene and cell therapy »
- Guillaume Canaud, FR « Targeted therapy for patients with PIK3CA-related overgrowth spectrum »
- Laura de Rosa, IT « Combined cell & gene therapy for Epidermolysis Bullosa »
- Arjan Lankester, NL & Frank Staal, NL
- Fernardo Larcher, ES « Advances in cell and gene therapy for genodermatoses. A focus in Epidermolysis Bullosa. »
- Carl Morris, USA
Social event, 18h30 To be confirmed
SATURDAY, MARCH 18th
Session F, 9 to 12, selected oral presentations and “Patients engagement and treatment access »
- Durhane Wong-Rieger, CA
- Nicole Boice, USA – TBC
- Nick Sireau, UK The AKU Story: collaborative drug development in action »
- Samuel Agyei Wiafe, Ghana
- Yarlalu Thomas, AU – TBC
Best posters prize & Closing Ceremony
Program updated November 04, 2022
